Zoeken
Algemene medische oncologie

Klinische studies lymfomen

Op deze pagina

Planned

There are currently no planned studies in our center.

Ongoing

RADAR - 1913LYMG

A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma (RADAR)

  • Principal investigator : Dr. S. Woei-A-Jin
  • Sponsor : EORTC - University collega London - Takeda
  • More information : NCT04685616
  • Indication : 
  • Internal reference number : s67806

M22-128

A Phase 3, Open-Label, Randomized Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4)

  • Principal investigator : Dr. S. Woei-A-Jin
  • Sponsor : AbbVie
  • More information : NCT06508658
  • Indication : Diffuse Large B-Cell Lymphoma
  • Internal reference number :  s68728

GCT3013-06 

A randomized, open-label, multicenter, global, phase 2 trial to evaluate the affecacy and sefety of epcoritamab as monotherapy or in comination with lenalidomide as first-line therapy for anthracycline-ineligible subjects with diffuse large B-cell lymphoma

Closed

COBRA EORTC-1537-LYMG

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

DEBIO 1562-201

A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma

  • Principal investigator : Dr. S. Woei-A-Jin
  • Sponsor : Debiopharm International SA
  • More information : NCT02564744
  • Indication : 
  • Internal reference number : s61617

GCT3013-05

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

MILLENNIUM C16027

An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies

  • Principal investigator : Prof. Dr. O. Bechter
  • Sponsor : Takeda / Millenium / PPD
  • More information : NCT02924272
  • Indication : 
  • Internal reference number : s59641

PIQUR PQR309-005

Open- label, non-randomized, phase 2 study evaluating efficacy and safety of PQR309 in patients with relapsed or refractory primary CNS lymphoma

PRISM MRG106-11-203

An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study

  • Principal investigator : Dr. S. Woei-A-Jin
  • Sponsor :  miRagen Therapeutics, Inc.
  • More information : NCT03837457
  • Indication : 
  • Internal reference number : s62802

RESMAIN 4SC-201-6-2015

A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy

SOLAR MRG106-11-201

A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

  • Principal investigator : Dr. S. Woei-A-Jin
  • Sponsor : miRagenTherapeutics, Inc.
  • More information : NCT03713320
  • Indication : 
  • Internal reference number : s61947

TAK-981-1002

An Open Label, Dose-Escalation, Phase I Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

  • Principal investigator : Dr. S. Woei-A-Jin
  • Sponsor :  Takeda
  • More information : NCT03648372
  • Indication : 
  • Internal reference number : s65683

TELLOMAK - IPH4102-201

T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

  • Principal investigator : Dr. S. Woei-A-Jin
  • Sponsor : Innate Pharma
  • More information : NCT03902184
  • Indication : 
  • Internal reference number : s65862

VERVOLGSTUDIE SGN35-005 of C25001 - SGN35-010

An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma

Laatste aanpassing: 23 oktober 2024